Exposure to alendronate is associated with a lower risk of bone metastases in osteoporotic women with early breast cancer

BACKGROUND: Bisphosphonate (BP) treatment to prevent bone loss in breast cancer patients is already well established. However, data on the association between oral BP exposure before cancer diagnosis and disease outcomes in patients with early breast cancer are still scarce. Limited information is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Rouach, Vanessa, Goldshtein, Inbal, Wolf, Ido, Catane, Raphael, Chodick, Gabriel, Iton, Amit, Stern, Naftali, Cohen, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107893/
https://www.ncbi.nlm.nih.gov/pubmed/30148062
http://dx.doi.org/10.1016/j.jbo.2018.07.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107893/
https://www.ncbi.nlm.nih.gov/pubmed/30148062
http://dx.doi.org/10.1016/j.jbo.2018.07.011

Ejemplares similares